R-CHOP Alone Induces High Complete Response in Non-Bulky Large B Cell Lymphoma

Share this content:
Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage DLBCL.
Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage DLBCL.

SAN FRANCISCO—The addition of radiotherapy (RT) should be reserved for the minority of patients with non-bulky limited-stage diffuse large B cell lymphoma (DLBCL) who do not reach a complete response (CR) with R-CHOP alone (Abstract 393), investigators reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.

Preliminary results of the prospective randomized phase 3 study from the Lysa/Goelams Group found that 4 to 6 cycles of R-CHOP alone induced a very high CR rate “with a very good overall survival and a very low relapse rate,” said Thierry Lamy, MD, PhD, of the Hematology Department at INSERM U917/University Hospital of Rennes in Rennes, France.

“The benefit of radiotherapy following chemotherapy in limited-stage DLBCL remains controversial,” he said, in explaining why the study was initiated in May 2005. Non-bulky was defined as a tumor size of less than 7 cm.

Patients with no modified International Prognostic Index (IPI) risk factors received 4 consecutive cycles and those with at least 1 risk factor received 6 consecutive cycles of R-CHOP 14, with IFRT 40 Gy (151 patients) or without (50 patients). An additional 2 cycles of R-CHOP followed by RT were recommended for those who had a partial response (PR).

Of the 336 randomly assigned patients, 301 were evaluable for response. Of the 151 patients randomly assigned to radiotherapy, 7 (4%) declined treatment.

After 4 cycles, 124 patients (82%) in the R-CHOP arm and 129 (85%) in the R-CHOP plus RT arm had a complete response (CR); 16% and 12% of patients in each arm, respectively, had a PR. One patient in the R-CHOP arm and 2 in the R-CHOP plus RT had stable disease.

Of the 43 patients who had PRs at cycle 4, 37 (86%) received 2 additional cycles of R-CHOP and RT and 6 had another regimen with and without RT; 40 of those patients entered CR, Dr. Lamy said.

At a median follow-up of 51 months (range, 2-100 months), 20 patients had relapsed at a median time to relapse of 21 months (range 4-93), 12 in the R-CHOP arm and 8 in the R-CHOP plus RT arm, a difference that was not statistically significant (P=0.27).

The event-free survival (EFS) and overall survival (OS) rates were not significantly different between arms; 5-year EFS was 88.4% in the R-CHOP arm versus 87.3% in the R-CHOP plus RT arm (hazard ratio [HR] 0.55; 95% confidence interval [CI] 0.26-1.17; P=0.13) and 5-year OS was 92% in the R-CHOP arm versus 90% in the R-CHOP plus RT arm (HR 0.60; 95% CI 0.23-1.62; P=0.33).

Multivariate analysis of EFS and OS stratified by IPI scores 0, 1, 2, and 3 showed significantly lower rates with increasing risk score (P=0.0015 for EFS and P=0.001 for OS).

Sixteen patients died: 9 from progressive disease, 1 from toxicity, 1 from acute leukemia, 1 from a solid tumor, 1 from a car crash, and 3 patients died from unknown causes.

  1. Lamy, Thierry, MD, PhD, et al. "393 R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL):  Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group." ASH 2014. Oral Presentation. December 8, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs